Patents Examined by Sagar Patel
  • Patent number: 11905244
    Abstract: Methods of identification of inhibitors of calcium release-activated calcium (CRAC) channel and small molecule inhibitors of CRAC channel, including methods of their synthesis and pharmaceutical use, are disclosed.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: February 20, 2024
    Assignee: The Texas A&M University System
    Inventors: Yubin Zhou, Lian He
  • Patent number: 11891384
    Abstract: The present invention relates to the novel key intermediate, 4-{4-[(SS)-(Aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]-phenyl}-morpholin-3-one perchlorate, m the synthesis of rivaroxaban. The invention further relates to the crystalline form of novel intermediate, the process to prepare the novel intermediate and method of preparing rivaroxaban using this novel intermediate. The invention provides an improved and efficient process for preparation of Rivaroxaban.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: February 6, 2024
    Assignee: Unichem Laboratories Ltd
    Inventors: Dhananjay G. Sathe, Arijit Das, Sanjay Raikar, Yashwant S. Surve, Bhushan S. Pandit
  • Patent number: 11857550
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: January 2, 2024
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States Government as Represented By the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Patent number: 11845723
    Abstract: The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: December 19, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Masaaki Sawa, Mai Arai, Ryoko Nakai, Hirokazu Matsumoto, Catherine Pugh, Eric Hu, Juan Guerrero, Jesse Jacobsen, Jonathan William Medley, Jie Xu, Latesh Lad, Leena Patel, Michael Graupe, Qingming Zhu, Stephen Holmbo, Tetsuya Kobayashi, Will Watkins, Yasamin Moazami, Suet C. Yeung, Julian A. Codelli, Heath A. Weaver
  • Patent number: 11820728
    Abstract: Compounds are provided having one of the following structures (I) or (II): or (I) (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3a, R3b, L1, L2, G1a, G1b, G2a, G2b and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: November 21, 2023
    Assignee: Acuitas Therapeutics, Inc.
    Inventors: Xinyao Du, Steven M. Ansell
  • Patent number: 11813330
    Abstract: A method for destroying cells and/or microorganisms in an organism includes the following steps: (a) administering to the organism a composition including a sonosensitizing compound containing at least one transition metal with three bidentate ligands; and (b) exposing the sonosensitizing compound in the organism to ultrasound, wherein the ultrasound is effective to activate the sonosensitizing compound to destroy at least one of the cells and the microorganisms in the organism. The ultrasound is preferably used in conjunction with electromagnetic therapies comprising photodynamic therapy, low-level laser therapy, and radiation therapy. The ultrasound is preferably administered at a duty cycle in the range from 5% to 95% at a power density of 10 W/cm2 and a frequency in the range from 10 Hz to 10 MHz.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: November 14, 2023
    Assignee: THERALASE TECHNOLOGIES, INC.
    Inventors: Arkady Mandel, Roger Dumoulin-White
  • Patent number: 11771677
    Abstract: Defined herein are immunomodulating Formula (1) compounds wherein R, R0, R1, R2, R3 and W are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof; and compositions comprising said compounds. The invention also includes methods for treating an inflammatory and/or immunological disease or disorder in an animal by administering a therapeutically effective amount of a Formula (1) compound, stereoisomer thereof, and a pharmaceutically acceptable salt thereof; or use of said compound of Formula (1) to prepare a medicament for treating an inflammatory and/or immunological disease or disorder in an animal.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: October 3, 2023
    Assignee: Zoetis Services LLC
    Inventors: Mark R. Cox, Timothy L. Stuk, Todd M. Maddux, Richard Andrew Ewin, Paul D. Johnson, Tomasz Respondek, Graham M. Kyne, Rajendran Vairagoundar
  • Patent number: 11753436
    Abstract: Described herein, inter alia, are compositions and methods for treating or preventing obesity and using the same.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: September 12, 2023
    Assignee: ERX Pharmaceuticals Corporation
    Inventors: Ralph Mazitschek, Yanbing Ding, Kaisheng Shen
  • Patent number: 11746172
    Abstract: The invention provides novel polymer-protein conjugates and molecular assemblies for controlled intracellular delivery of proteins, and compositions and methods of preparation and use thereof.
    Type: Grant
    Filed: July 19, 2020
    Date of Patent: September 5, 2023
    Assignee: University of Massachusetts
    Inventors: Sankaran Thayumanavan, Bin Liu
  • Patent number: 11746104
    Abstract: Provided herein are compounds, compositions, and methods useful for the treatment of breast cancer, particularly triple negative breast cancers. In certain aspects, provided herein are compounds of formula (I): or a pharmaceutically acceptable salt or solvate thereof. In certain aspects, provided herein are compositions comprising any of the compounds provided herein. In certain aspects, provided herein are methods for the treatment of cancer in a subject in need thereof comprising administering to the subject an effective amount of any of the compounds or compositions provided herein.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: September 5, 2023
    Assignee: QATAR UNIVERSITY
    Inventors: Ashraf Khalil, Ala-Eddin Al Moustafa, Dana H. Elkhalifa, Feras Alali
  • Patent number: 11739063
    Abstract: Disclosed is a compound of formula (I) in which R1, R2, and R3 are as described herein. Also provided are pharmaceutical compositions comprising the compound of formula (I) and methods of using the compound of formula (I), including a method of treating a disease or disorder and a method for effectuating a G-protein coupled receptor (GPCR)-mediated response in a subject.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: August 29, 2023
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Johns Hopkins University
    Inventors: Jordi Bonaventura, Juan Luis Gomez, Andrew Horti, Feng Hu, Michael Michaelides, Martin Pomper, Marta Sanchez-Soto
  • Patent number: 11702436
    Abstract: The invention relates to tungsten oxo alkylidene complexes ligated with a tetraphenylphenoxy ligand and a neutral ligand such as a phosphine or a pyridine, and method of making the complexes. The complexes are useful as catalysts for performing a ring-opening metathesis polymerization of dicyclopentadiene to poly(dicyclopentadiene).
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: July 18, 2023
    Assignee: Verbio Vereinigte BioEnergie AG
    Inventors: Henrik Gulyas, Benedek Vakulya
  • Patent number: 11679093
    Abstract: The present invention relates in certain aspects to the discovery of novel 2-naphthimidamide compounds that are capable of binding Type II Transmembrane Serine Proteases (TTSPs). In certain embodiments, the compounds of the invention can be used to treat or prevent Influenza A viral infection in a mammal.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: June 20, 2023
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventor: Kambez Hajipouran Benam
  • Patent number: 11667754
    Abstract: A tetracarboxylic dianhydride includes: at least one acid dianhydride (A) selected from the group consisting of compounds each having an endo/exo type three-dimensional structure represented by a particular general formula and their enantiomeric compounds each having an exo/endo type three-dimensional structure; and/or an acid dianhydride (B) having an endo/endo type three-dimensional structure represented by a particular general formula, wherein a content of the acid dianhydride (B) in a total amount of the acid dianhydrides (A) and (B) is 30 to 100% by mole in a mole ratio.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: June 6, 2023
    Assignee: ENEOS CORPORATION
    Inventors: Yusuke Matsuo, Daisuke Watanabe, Takahiro Hasegawa
  • Patent number: 11660291
    Abstract: The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1/CXCR2 receptor inhibitors, useful in the treatment and/or prevention of some sarcomas, preferably in the treatment and/or prevention of osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: May 30, 2023
    Assignees: Dompe' Farmaceutici S.P.A., Research Institute at Nationwide Children's Hospital
    Inventors: Ryan David Roberts, Laura Brandolini
  • Patent number: 11660280
    Abstract: The present disclosure describes the use of 2,4-disulfonyl phenyl tert-butyl nitron (2,4-ds-PBN) in the treatment of temozolomide drug resistant gliomas. The 2,4-ds-PBN may be used combined with other chemo- and radiotherapies and surgery, including temozolomide, to reduce glioma occurrence, recurrence, spread, growth, metastasis, and vascularization, and to inhibit development of temozolomide resistance.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: May 30, 2023
    Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventor: Rheal A. Towner
  • Patent number: 11655209
    Abstract: A process for synthesizing an azo compound by oxidation of a hydrogen compound in the presence of a catalyst and a compound of formula (I) is described in which R1, R2 and R3 (R1)(R2)C(PO3(R3)2)2??(I) are as defined. The use of a compound of formula (I) as complexing agent for a catalyst is also described.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: May 23, 2023
    Assignee: Arkema France
    Inventors: Jean-Marc Sage, Jean-Michel Bossoutrot
  • Patent number: 11643419
    Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV and formula V and the methods for the treatment of xerostomia may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral mucosal inflammatory, dry mouth or oral dry mouth mediated infectious diseases.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: May 9, 2023
    Assignee: Cellix Bio Private Limited
    Inventor: Mahesh Kandula
  • Patent number: 11634414
    Abstract: Provided is a hetero-cyclic compound of Chemical Formula 1: and an organic light emitting device comprising the same.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: April 25, 2023
    Assignee: LG CHEM, LTD.
    Inventors: Seongmi Cho, Wanpyo Hong, Dong Hoon Lee, Jungoh Huh, Min Woo Jung, Jungha Lee
  • Patent number: 11623009
    Abstract: Aspects of the present disclosure generally relate to compounds for targeting and healing bone fractures. Some of these compounds include a negatively charged oligopeptide comprising an acidic oligopeptide, a linker, which may be hydrolyzable or may be a substrate for the protease cathepsin K, and at least one molecule that promotes bone healing. In some compounds the molecule that promotes bone healing is an anabolic compound that inhibits GSK3?, in some compounds the molecule that promotes the healing of bone fracture is a pro-inflammatory agent such as PGE1. Other embodiments include methods of treating a bone fracture comprising administering a therapeutic amount of any one of the compounds disclosed herein.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: April 11, 2023
    Assignees: Purdue Research Foundation, University of Utah
    Inventors: Stewart Andrew Low, Philip S. Low, Christopher Galliford, Jindrich Kopecek, Jiyan Yang